AABB award makes Biovault the UK’s most highly accredited cord blood and tissue bank
Biovault has confirmed its position as the UK’s most highly accredited private human blood and tissue bank after passing a rigorous audit and inspection by a prestigious international quality standard.
The AABB accreditation now proudly sits alongside a string of major quality standards at the Plymouth-based company. According to the AABB (formerly the American Association of Blood Banks), their accreditation “promotes the highest standards for medical, technical and administrative performance, scientific investigation, clinical application and education.”
Since starting up in 2002, Biovault, which is part owned by Plymouth University, has released over 4000 stem cell samples for transplantation – more than any other cord blood and tissue bank in the UK. Many of these transplants have been in conjunction with the UK NHS and South West Peninsula blood and marrow transplant service, but transplants have also taken place in the US with Duke University in North Carolina where stem cells from blood in the umbilical cord has been used for a pioneering treatment of cerebral palsy. The company has also processed, stored and released cord blood samples which have been used in the treatment of Acute Lymphoblastic Leukaemia, Neuroblastoma, Sickle Cell Disease and Thalassemia worldwide.
Currently the only private blood and tissue bank to be trusted and used by the the NHS; Biovault also holds the JACIE accreditation – Europe’s Highest Standard, along with ISO 9001 and 13485 and is licensed by the Human Tissue Authority.
In addition to providing stem cell and umbilical cord blood storage for customers across the United Kingdom, Biovault also works with partners in Bahrain, Dubai, Italy, Jordan, Malta and Switzerland.
Commenting on the new accreditation, Kate Sneddon, CEO at Biovault said: “The AABB accreditation further enhances our reputation for the highest quality processes and procedures and recognises the scientific and technical excellence of our expert team. We look forward to further contributing to advances in cord blood and tissue research as both institutional and public awareness grows.”